Online Only Articles

Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma

Service and Central Laboratory of Hematology, University Hospital Lausanne (CHUV), Switzerland
Service and Central Laboratory of Hematology, University Hospital Lausanne (CHUV), Switzerland
Service and Central Laboratory of Hematology, University Hospital Lausanne (CHUV), Switzerland
Institute of Pathology, University Hospital Lausanne (CHUV), Switzerland
Institute of Pathology, University Hospital Lausanne (CHUV), Switzerland
Department of Oncology, CHUV, University Hospital of Lausanne, Switzerland
Department of Oncology, CHUV, University Hospital of Lausanne, Switzerland
Service and Central Laboratory of Hematology, University Hospital Lausanne (CHUV), Switzerland
Vol. 103 No. 1 (2018): January, 2018 https://doi.org/10.3324/haematol.2017.179150